SARS-CoV-2 Spike Produced in Insect Cells Elicits High Neutralization Titres in Non-Human Primates.
Tingting Li,Qingbing Zheng,Hai Yu,Dinghui Wu,Wenhui Xue,Hualong Xiong,Xiaofen Huang,Meifeng Nie,Mingxi Yue,Rui Rong,Sibo Zhang,Yuyun Zhang,Yangtao Wu,Shaojuan Wang,Zhenghui Zha,Tingting Chen,Tingting Deng,Yingbin Wang,Tianying Zhang,Yixin Chen,Quan Yuan,Qinjian Zhao,Jun Zhang,Ying Gu,Shaowei Li,Ningshao Xia
DOI: https://doi.org/10.1080/22221751.2020.1821583
2020-01-01
Emerging Microbes & Infections
Abstract:The current coronavirus disease 2019 (COVID-19) pandemic was the result of the rapid transmission of a highly pathogenic coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), for which there is no efficacious vaccine or therapeutic. Toward the development of a vaccine, here we expressed and evaluated as potential candidates four versions of the spike (S) protein using an insect cell expression system: receptor binding domain (RBD), S1 subunit, the wild-type S ectodomain (S-WT), and the prefusion trimer-stabilized form (S-2P). We showed that RBD appears as a monomer in solution, whereas S1, S-WT, and S-2P associate as homotrimers with substantial glycosylation. Cryo-electron microscopy analyses suggested that S-2P assumes an identical trimer conformation as the similarly engineered S protein expressed in 293 mammalian cells but with reduced glycosylation. Overall, the four proteins confer excellent antigenicity with convalescent COVID-19 patient sera in enzyme-linked immunosorbent assay (ELISA), yet show distinct reactivities in immunoblotting. RBD, S-WT and S-2P, but not S1, induce high neutralization titres (>3-log) in mice after a three-round immunization regimen. The high immunogenicity of S-2P could be maintained at the lowest dose (1 mu g) with the inclusion of an aluminium adjuvant. Higher doses (20 mu g) of S-2P can elicit high neutralization titres in non-human primates that exceed 40-times the mean titres measured in convalescent COVID-19 subjects. Our results suggest that the prefusion trimer-stabilized SARS-CoV-2 S-protein from insect cells may offer a potential candidate strategy for the development of a recombinant COVID-19 vaccine.